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Abstract
In December 2019, first cases of a novel coronavirus were identified in Wuhan, China. A state of global pandemic 
was shortly declared among a very rapid contagious spread of the virus. The causative virus was identified as the 
SARS-CoV-2 viruses and is genetically related to the previous SARS outbreak in 2003. The virus causes a wide 
clinical spectrum from mild flu-like symptoms to adult respiratory distress syndrome. Kidney involvement has been 
reported in several reports in patients with various degrees of severity of SARS-CoV-2 infection. As knowledge is 
evolving, the accurate incidence of acute kidney injury (AKI) is not known. Many questions are yet to be answered 
regarding the effect of epidemiological variables and comorbidities on the occurrence of AKI. Some reports have 
observed the occurrence of hematuria and proteinuria in a percentage of infected patients. Moreover, chronic 
kidney disease has not been found, in some reports to add to the adverse outcomes, an aspect that merits further 
exploration. Patients on regular hemodialysis may be vulnerable to coronavirus infection due to the lower status of 
immunity and the need for frequent attendance at health-care facilities. Due to the previous factors, prevention and 
mitigation of the SARS-CoV-2 virus, in this vulnerable population, constitutes a major challenge.
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Introduction
Origin and epidemiology
SARS-CoV-2 is a novel mutant of the 
coronavirus family that is causing the most recent and 
ongoing pandemic. The coronavirus is thought to have 
been transmitted at first instance from bats to humans. 
A wet wild animal market is likely considered to be the 
primary focus. The first cases of human infections were 
then reported in the city of Wuhan, the capital of Hubei 
Province of China. This was followed by widespread 
of the pandemic to many countries around the globe. 
Until the time of writing this paper (April 6, 2020), the 
number of infected people around the globe exceeded 
1,300,000 patients with mortality over 74,000 [1].
Pathogenesis
COVID-19 primarily targets the respiratory 
system, causing a wide clinical spectrum from mild 
symptoms to adult respiratory distress syndrome. The 
pathogenesis is mediated in severe cases through 
the so-called cytokine storm (Figure 1). This involves 
the secretion of large amounts of pro-inflammatory 
cytokines and chemokines including IL8, IL 6, IL9, 
IL10, and many others. Pathogenic mechanisms in 
the kidneys are not fully elucidated, but the suggested 
mechanisms are through attachment of the virus to 
ACE2 receptors. Excess secretion of cytokines leads 
to multiorgan failure in a percentage of patients, 
including acute kidney injury (AKI), through tissue 
hypoxia [2].
Figure 1: Renal complications of SARS-CoV-2  virus
Chronic kidney disease (CKD) as a 
predisposing comorbidity in the event of COVID-19
A number of studies have analyzed patients’ 
comorbidities. The prevalence of CKD was variable across 
studies, ranging from 0.7 to 6.5% [3]. Only one cohort 
of 710 patients reported that 40% of patients had CKD 
in the form of deranged kidney function, hematuria, or 
proteinuria [4]. Most studies that used regression analysis 
to predict poor outcome have not identified chronic kidney 
disease as an important prognostic factor [5]. The lack 
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of stratification of CKD among the prognostic factors 
of SAR-CoV-2 denotes that patients with CKD are not 
particularly at a higher risk of SAR-CoV-2 infection [3], [5].
Patients with end-stage renal disease (ESRD) 
on hemodialysis have a lower immunity status to various 
types of infections. The impact of COVID-19 infection on 
hemodialysis patients merits further investigation. In a 
study of 230 patients on hemodialysis in Wuhan, during 
the COVID-19 outbreak, 37 patients and 4 health-care 
providers became infected. The clinical features of 
hemodialysis patients reported in this cohort were 
mild. Seven deaths occurred among dialysis patients 
during the outbreak; however, causes of death were not 
attributed to COVID-19 [6].
AKI as a complication of COVID-19
Acute kidney injury is a common complication 
of several infections. In the previous SARS-CoV-2 
outbreak in 2003, the incidence of AKI was as low as 
6% [2], [7]. Nevertheless, AKI case fatality rate was 
high [8]. As for SARS-CoV-2, the exact incidence of AKI 
is not well known. Cohorts that reported AKI incidence 
are summarized in Table 1 [9],[10], [11], [12], [13], [4], 
[3], [14], [15], [16], [17], [18], [19], [20], [21], [5].
There is heterogeneity among studies 
regarding the reported incidence of AKI. This may be 
attributed to inconsistencies in applying AKI definitions 
or due to genetic variability that merits further studies.
Some reports have shown that the incidence of 
AKI is significant, while others report that the incidence 
is marginal. Guan et al. have shown, in a large cohort 
of confirmed COVID-19 cases that the prevalence of AKI 
was as low as 0.5%. This increased in patients with severe 
COVID-19 to 2.9% [5]. In other cohorts, the incidence of 
AKI in confirmed cases of COVID-19 was higher.
In two cohorts, the reported incidence of AKI 
was notably higher. In a cohort of 193 patients, the 
overall incidence of AKI was 28% and the incidence in 
severe cases was 66% [18]. In another cohort of 191 
patients, the incidence of AKI in non-survivors was 
50% [19]. In the study by Hu et al., AKI was present in 
17 of all 323 patients (5.3%); however, the incidence 
of AKI in patients with critical COVID-19 was 38.5%. 
Furthermore, in this cohort, most patients who had AKI 
(14 out of 17) had unfavorable outcomes [17].
Interestingly, one retrospective study of 116 
patients showed that the changes in kidney function 
throughout the disease course were subtle [13]; 
this study included five patients on maintenance 
hemodialysis, all of whom had severe disease but 
survived. Despite the subtle changes in kidney 
function, none of patients in this cohort met the 
defining criteria for AKI, including seven deaths that 
were reported [13]. This report concluded that AKI and 
other kidney diseases are not of paramount clinical 
significance in patients with COVID-19 [13].
During a previous SARS outbreak in 2003, a 
study of postmortem kidney biopsies examined using 
electron transmission microcopy, failed to detect any 
viral particles in kidney tissues. This finding supports 
the theory that most of the kidney pathogenesis in the 
earlier SARS outbreak was in the context of multiorgan 
failure. The pathogenesis of AKI may be multifactorial. 
Suggested mechanisms are direct cytopathic effects on 
kidney tissues, as denoted by the retrieval of the viral 
RNA from urine samples [4]. The direct cytopathic effect 
of COVID-19 on kidneys is now more evident, as it has 
been shown that there is overexpression of both ACE2 
receptors and a cleavage spike protein in podocytes 
and proximal tubular cells [22]. This experimental 
evidence is of paramount importance and can explain 
proteinuria in patients with COVID-19. Interestingly, the 
latter experiment reports variable expression of cleaved 
S protein such that there is low expression in the 
Chinese race as compared to Caucasians. Important 
pathological evidence was reported by Diao et al. The 
pathology team managed to confirm the visualization 
of the SARS-CoV-2 viral particles in the renal tubular 
cells of postmortem kidney biopsies [23], [24]. The 
difference in kidney tropism between SARS-CoV and 
SARS-CoV-2 may be attributed to the affinity to ACE2 
receptors in the kidneys.
Tissue hypoxia, in the context of massive 
cytokine secretion, is a key renal pathogenic 
mechanism. Rhabdomyolysis and raised creatinine 
kinase have been observed in a few cases [5]. It was 
also noticed in one cohort that AKI occurred later to 
acute cardiac injury, suggesting a temporal relationship 
between cardiac injury and AKI and the possible 
occurrence of cardiorenal syndrome [19]. In a recent 
single case report, collapsing variant of focal segmental 
glomerulosclerosis was diagnosed in renal biopsy 
of African-American woman, who tested positive to 
COVID-19. The patient presented with confusion and 
rapidly deteriorating kidney function, she improved 
markedly with the initiation of dialysis [25].
Hematuria and proteinuria
In the largest prospective cohort of kidney 
diseases in COVID-19, it was found that hematuria 
occurred in 26% of patients and proteinuria occurred 
in about 43% [4]. Large prevalence of proteinuria could 
be explained by the finding of the above-mentioned 
experimental study that showed expression of ACE 2 
receptors in podocytes and proximal tubular cells [22]. 
However, quantification of proteinuria, using 24 h 
urinary collection or protein to creatinine ratio, was not 
done within the investigation battery. Kidney biopsy has 
not been attempted in any patient. In this prospective 
report, the presence of hematuria or proteinuria signaled 
poor outcome, as measured by in-hospital mortality.
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Effect of dialysis modalities on survival in 
patients infected with COVID-19
Continuous renal replacement therapy (CRRT) 
is a modality of dialysis that implies increasing the 
clearance of solutes through convection, diffusion, 
ultrafiltration, and adsorption. The modality has benefits 
in critically ill patients, including the removal of septic 
toxins in addition to correction of the uremic status. 
There is accumulating evidence that critically ill patients 
who develop AKI may have lower mortality if they are 
treated using CRRT [26].
As knowledge is evolving about the SARS-
CoV-2 virus, the benefit of CRRT in the management 
of critically ill patients with COVID-19 is much less 
clear. One retrospective study was conducted in China 
on 36 confirmed COVID-19 cases who have been 
admitted to the intensive care unit [10]. All patients were 
mechanically ventilated; the aim was to compare the 
effect of CRRT as compared to conventional dialysis. 
Patients were followed up for an average time of 10.4 
days. The mean serum creatinine was slightly higher 
in patients who received CRRT than in patients who 
did not receive CRRT (94.5 mmol/L vs. 72 mmol/L, 
p=0.017). There was a marginally a favorable effect of 
CRRT in terms of adjusted mortality (54.4% in CRRT 
group vs. 78% in the conventional hemodialysis group).
On the contrary, another analysis of risk 
factors and survival in critically ill patients found that 
non-survivors received more treatment with CRRT than 
survivors.
Another study of 101 case fatalities in China, 
five cases had CRRT. Two patients died within 3 days 
and three patients died after 3 days. The mean baseline 
serum creatinine was 139.8 µmol/L [27]. In another 
large retrospective analysis by Guan et al., nine patients 
were treated with CRRT, eight of whom died suggesting 
that CRRT had no mortality benefit [5]. In a cohort of 
191 patients, 10 patients received renal replacement 
therapy, and all did not survive, suggesting that renal 
replacement therapy in severe cases of COVID-19 may 
not have any survival benefit [19].
Renal-specific mortality due to COVID-19
The leading causes of mortality in COVID-19-
infected patients are sepsis and ARDS. This has been 
observed in several cohorts. A large prospective study 
showed that the development of AKI in patients infected 
with COVID-19 was associated with four-fold increase in 
the mortality [4]. In other reports, renal-specific causes 
were not the most common or the second most common 
of mortality in COVID-19. In a retrospective study of 101 
non-surviving COVID-19 patients, the incidence of AKI 
was 23%, there was no significant difference between 
patients who died within 3 days and patients who died later 
with regard to AKI incidence (25% vs. 21%, p=0.611) [27]. 
In this cohort, AKI was the 3rd leading cause of death 
after respiratory and cardiovascular causes. In a single-
centered study in China, chronic kidney disease was 
present in 7 out of 323 patients (2%). Four patients 
had severe disease while the other three patients had 
non severe disease. Elevation of BUN > 88 mmol/L 
was associated with a two-fold increase in the chance 
of poor clinical outcomes. Baseline serum creatinine of 
<88 mmol/L was associated with 63% reduction in the 
development of poor outcomes. In another report of 82 
non-surviving patients with confirmed COVID-19, the 
AKI percentage was 31% [28].
Prevention and mitigation of COVID-19 
among dialysis patients
Until the time of writing this paper, there is no 
consensus or formal approval of any medication for 
COVID-19. This fact mandates the exhaustion of all 
measures to prevent the transmission of infection. In this 
respect, the Centers for Disease Control and Prevention 
(CDC) has issued an interim guideline for hemodialysis 
centers. The guideline emphasizes the importance 
of early recognition and isolation of cases while 
attending their scheduled sessions [29]. This mandates 
treating confirmed cases of COVID-19 hemodialysis 
in designated rooms with droplet infection prevention 
precautions; patients with confirmed of suspected 
COVID-19 should be separated by 6 feet distance. 
The instructions for hemodialysis patients should be 
centralized around reporting any new symptoms of fever 
or cough. Patients should be instructed on the proper 
use of face masks and using tissues when sneezing or 
coughing to prevent spread of infections [30], [29]. There 
is an anticipated extraordinary strain on hemodialysis 
facilities. In parallel, there are a number of suggestions 
to match the resources. These practical suggestions 
aim at reduction of the strain on hemodialysis units [29].
Summary and Conclusion
SARS-CoV-2 (COVID-19) virus pandemic 
constitutes a global health threat. The disease 
spectrum caused by the virus flu-like symptoms to adult 
respiratory distress syndrome. Kidney involvement 
in COVID-19 has been reported in previous cohorts. 
Acute kidney injury is a complication of COVID-19, 
either as part of multiorgan failure caused by excess 
cytokine production or through direct cytopathic effect 
on renal tissue. Overexpression of ACE2 receptors 
in podocytes and proximal tubular cells has been 
observed in patients with COVID-19. Other renal 
manifestations include proteinuria and hematuria. The 
true incidence and outcome of AKI in COVID-19 is not 
entirely clear and merits further studies. Continuous 
renal replacement therapy (CRRT) benefits in case of 
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AKI are controversial. Patients on hemodialysis may 
be at increased risk of COVID-19 due to the nature of 
renal replacement therapy that requires 3 times weekly 
attendance at dialysis facilities. This necessitates the 
application of meticulous measures to prevent and 
mitigate the outbreak in patients on hemodialysis.
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